Bafilomycin A1; Streptomyces griseus

Biochem/physiol Actions

Primary Targetvacuolar type H⁺ ATPase

General description

Note: 1 set = 3 x 10 µg

A macrolide antibiotic that acts as a specific inhibitor of vacuolar-type H⁺-ATPase (V-type; K_i = 500 pM). A valuable tool for distinguishing among different types of ATPases. Blocks lysosomal cholesterol trafficking in macrophages and is known to interfere with pH regulation in brain cells. Exhibits cytotoxic effects on a number of cell lines in a cell viability assay. Reported to selectively inhibit β-secretase, an enzyme involved in the processing of amyloid precursor protein (APP). The InSolution™ format with a purity of ≥97% by HPLC in 90% DMSO is also available (Cat. No. 508409).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Sinha, S., and Lieberburg, I. 1999. Proc. Natl. Acad. Sci. USA96, 11049.Calvert, C.M., and Sanders, D. 1995. J. Biol. Chem.270, 7272.Nishihara, T., et al. 1995. Biochem. Biophys. Res. Commun.269, 255.Crider, B.P., et al. 1994. J. Biol. Chem.269, 17379.Palokangas, H., et al. 1994. J. Biol. Chem.269, 17577.Sundquist, K.T., and Marks, S.C., Jr. 1994. J. Bone Miner. Res.9, 1575.Drose, S., et al. 1993. Biochemistry32, 3902.Furuchi, T., et al. 1993. J. Biol. Chem.268, 27345.Bowman, E.J., et al. 1988. Proc. Natl. Acad. Sci. USA85, 7972.

Packaging

1 set in Glass bottle

10 µg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 1 year at -20°C.

Warning

Toxicity: Carcinogenic / Teratogenic (D)